Sign up Australia
Proactive Investors - Run By Investors For Investors

Patrys secures $3.5 million for anti-cancer therapies

The single tranche placement will see new shares issued priced at 3.4 cents.
sign saying funding
The capital raising was oversubscribed by investors

Patrys Ltd (ASX:PAB) has received firm commitments from institutional and sophisticated investors to raise $3.5 million through a share placement priced at 3.4 cents.

Funds raised will be used to accelerate the development of Patrys’ Deoxymab platform, which was licensed from Yale University in March 2016.

Patrys has established a strong position in the field of DNA damage repair (DDR) therapeutics with a novel approach that utilizes cell-penetrating antibodies to selectively kill cancer cells.

The company also has a range of new pre‐clinical studies planned to create shareholder value by supporting business development efforts.

Developing anti‐cancer therapies based on the Deoxymab platform

Patrys’ CEO and managing director Dr James Campbell said: “Patrys is pleased to announce that this over‐subscribed share placement attracted strong demand from institutional investors.

“We believe this result is indicative of strong investor interest in our efforts to develop anti‐cancer therapies based on the Deoxymab platform, which has created a novel position in the field of DNA damage repair antibody therapeutics.”

View full PAB profile View Profile

Patrys Timeline

Newswire
January 11 2018

Related Articles

People working in a laboratory
May 02 2018
The benefits of Admedus' proprietary ADAPT technology and products are now scientifically proven beyond doubt.
Drug discovery
April 04 2018
In the group’s 2017 results statement at the end of March, Ray Barlow - who took over as CEO on 6 April 2017 - commented: “We are now focused on the right activities"
tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use